Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
This study is currently recruiting participants.
Verified by Toyama Chemical Co., Ltd., September 2009
First Received: April 18, 2008   Last Updated: September 16, 2009   History of Changes
Sponsor: Toyama Chemical Co., Ltd.
Information provided by: Toyama Chemical Co., Ltd.
ClinicalTrials.gov Identifier: NCT00663936
  Purpose

The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment.

The secondary objectives of the study are to evaluate the safety of T-817MA and the activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.


Condition Intervention Phase
Alzheimer's Disease
Drug: T-817MA
Drug: Placebo
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Toyama Chemical Co., Ltd.:

Primary Outcome Measures:
  • Evaluation of the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary objectives are to evaluate the safety of T-817MA and the activities of daily living (ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 326
Study Start Date: April 2008
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
T-817MA once daily
Drug: T-817MA
224 mg T-817 MA once daily
2: Placebo Comparator
Placebo once daily
Drug: Placebo
Placebo once daily

  Eligibility

Ages Eligible for Study:   50 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female (post-menopausal or surgically sterile)
  2. Patients with Mild to moderate Alzheimer's disease who are receiving Donepezil.
  3. Age 50 to 90 inclusive
  4. Patients must be living in the community
  5. Patients must have an eligible informant or study partner (caregiver)
  6. Patients and eligible informant or study partner (caregiver) must be able to read and understand English.
  7. Informed consent obtained from both the patient and the caregiver etc (According to the protocol)

Exclusion Criteria:

  1. Patients with clinically significant cardiac, hepatic or renal impairment
  2. Patient have a dementia not of the Alzheimer's type etc (According to the protocol)
  3. Patients who are taking any drug other than donepezil for Alzheimer's disease, including rivastigmine (Exelon®), galantamine (Razadyne®), memantine (Namenda™) or tacrine (Cognex®) taken within twelve (12) weeks of the Baseline Visit (Visit 2).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00663936

Contacts
Contact: Jeremy Johnston 1-800-554-0502 ext 294 JJohnston@incresearch.com

  Hide Study Locations
Locations
United States, Arizona
Northwest NeuroSpecialists Recruiting
Tucson, Arizona, United States, 85741
Contact: Joan Laguna, CCRC     520-742-1833     jlaguna@neuroresearch.com    
Principal Investigator: Jeanette Wendt, MD            
Banner Alzheimer's Institute Recruiting
Phoenix, Arizona, United States, 85006
Contact: Stephanie Reeder     602-239-6279     stephanie.reeder@bannerhealth.com    
Principal Investigator: Pierre Tariot, M.D.            
United States, California
San Francisco Clinical Research Center Recruiting
San Francisco, California, United States, 94109
Contact: Michael Miller     415-673-4600     sfhaclin@aol.com    
Principal Investigator: Jerome Goldstein, MD            
Southwest Institute for Clinical Research, Inc. Recruiting
Rancho Mirage, California, United States, 92270
Contact: Linda Roger, RN     760-464-2124     LRogerRN@aol.com    
Principal Investigator: Richard Hubbard, MD            
Pacific Research Network, Inc. Recruiting
San Diego, California, United States, 92103
Contact: Bud Gaydos, LVN     619-294-4302     bgaydos@prnsd.com    
Principal Investigator: Stephen G Thein, PhD            
United States, Colorado
Radiant Research Recruiting
Denver, Colorado, United States, 80239
Contact: Burlleen Hewitt     303-480-7122     burlleen.hewitt@radiantresearch.com    
Principal Investigator: Leslie Moldauer, MD            
United States, Connecticut
Geriatric and Adult Psychiatry, LCC Recruiting
Hamden, Connecticut, United States, 06518
Contact: Andrea DeClement     203-288-0414     adeclement@geriatrics-psych.com    
Principal Investigator: Alan Siegal, MD            
Research Center for Clinical Studies, Inc. Recruiting
Norwalk, Connecticut, United States, 06851
Contact: Suman Thapamagar     203-838-0070     sthapamagar@rccsmail.com    
Principal Investigator: Bart A Sloan, M.D.            
United States, Florida
Axiom Clinical Research of Florida Recruiting
Tampa, Florida, United States, 33609
Contact: Kathleen Carlson     813-353-9613     kcarlson.axiom@verizon.net    
Principal Investigator: Susan J Steen, MD            
Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute Recruiting
Tampa, Florida, United States, 33613
Contact: Marianne Chanti-Ketterl     813-396-0621     mchantik@health.usf.edu    
Principal Investigator: Ashok Raj, MD            
Premiere Research Institute Recruiting
West Palm Beach, Florida, United States, 33407
Contact: Teresa Villena     561-845-0500 ext 142     tvillena@aol.com    
Principal Investigator: Carl Sadowsky, MD            
Renstar Medical Research Recruiting
Ocala, Florida, United States, 34471
Contact: Pat Riddle     352-629-5800     renstar@renstar.net    
Principal Investigator: John P Nardandrea, M.D.            
NeuroPsychiatric Center of the Palm Beaches Recruiting
Boynton Beach, Florida, United States, 33426
Contact: Jacqueline Taylor     561-364-7257     jtaylor@neuropsychofpb.com    
Principal Investigator: Veronica Motiram, M.D.            
Anchor Research Center Recruiting
Naples, Florida, United States, 34102
Contact: Ginnie Hennes     239-643-8805     vhennes@anchorhealthcenters.com    
Principal Investigator: Ashley Tunkle, MD            
United States, Georgia
Columbus Research & Wellness Institute Recruiting
Columbus, Georgia, United States, 31907
Contact: Theresa Harris     706-653-0419     theresaharris10@hotmail.com    
Principal Investigator: Reinaldo Verson, MD            
United States, Indiana
Agewell Recruiting
Indianapolis, Indiana, United States, 46260
Contact: Rebecca Hancock, RN     317-846-9792     bhancock@agewell.biz    
Principal Investigator: Stephen Rappaport, MD            
United States, Nevada
Cleveland Clinic - Lou Ruvo Center for Brain Health Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Michelle Sholar     702-671-5058     sholarm@ccf.org    
Principal Investigator: Charles B Bernick, MD            
United States, New Jersey
Memory Enhancement Center of America Recruiting
Toms River, New Jersey, United States, 08755
Contact: Ashley Clayton     732-341-9500     aclayton@memorycenternj.com    
Principal Investigator: Joel S Ross, MD            
United States, New York
Alzheimer's Disease Center, U. of Rochester Medical Center Recruiting
Rochester, New York, United States, 14620
Contact: Bonnie Goldstein     585-760-6561     BonnieS_Goldstein@URMC.rochester.edu    
Principal Investigator: Anton Porsteinsson, MD            
Richmond Behavioral Associates Recruiting
Staten Island, New York, United States, 10312
Contact: Tatiana Kundla     718-317-5522     patakyova@rbany.com    
Principal Investigator: Mark DiBuono, MD            
Brooklyn Medical Institute Recruiting
Brooklyn, New York, United States, 11214
Contact: Lilit Asatryan     718-339-7711     lasatryan@gminstitutes.com    
Principal Investigator: Zinoviy Benzar, MD Ph.D.            
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27705
Contact: Debra Heydt     919-668-2843     debra.heydt@duke.edu    
Principal Investigator: James Burke, M.D.            
Clinical Trials of America, Inc. Recruiting
Winston Salem, North Carolina, United States, 27103
Contact: Kim Durkin     336-768-3456     kdurkin@ctamerica.net    
Principal Investigator: Beverly N Jones, III, M.D.            
The Alzheimer's Memory Center Recruiting
Charlotte, North Carolina, United States, 28211
Contact: Michelle Herrin     704-364-4000     mherrin@carolinasresearch.com    
Principal Investigator: Mohammad Bolouri, MD            
Raleigh Neurology Associates Recruiting
Raleigh, North Carolina, United States, 27607
Contact: Beth Jackson, LPN     919-782-3456 ext 8264     bjackson@raleighneurology.com    
Principal Investigator: Patricia Naslund, MD            
United States, Pennsylvania
CRI Worldwide, LLC Recruiting
Philadelphia, Pennsylvania, United States, 19139
Contact: Nicolette Laskowski     215-471-6859     nlaskowski@criww.com    
Principal Investigator: Daniel Gruener, M.D.            
United States, Texas
Innovative Clinical Trials Recruiting
San Antonio, Texas, United States, 78229
Contact: Elizabeth Hendrix     210-377-2873     Elizabeth.Hendrix@innovativeclincialtrials.com    
Principal Investigator: James E Garrison, MD            
United States, Wisconsin
IPC Research Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Anne Dobratz     262-513-0700 ext 230     annedobratz@sbcglobal.net    
Principal Investigator: Cary Kohlenberg, MD            
Canada, Ontario
Toronto Memory Program Recruiting
Toronto, Ontario, Canada, M3B 2S7
Contact: Atif Shaikh     416-386-9761     ashaikh@memorydisorders.ca    
Principal Investigator: Sharon Cohen, MD            
Sponsors and Collaborators
Toyama Chemical Co., Ltd.
  More Information

Additional Information:
No publications provided

Responsible Party: Toyama Chemical Co., Ltd. ( Dr. Katsumi Shimizu, Development Management Department )
Study ID Numbers: AA4437420
Study First Received: April 18, 2008
Last Updated: September 16, 2009
ClinicalTrials.gov Identifier: NCT00663936     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Toyama Chemical Co., Ltd.:
Alzheimer's Disease
Alzheimer's

Additional relevant MeSH terms:
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Alzheimer Disease
Central Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Brain Diseases
Dementia

ClinicalTrials.gov processed this record on November 22, 2009